David Hardten, MD
Ophthalmology · Minneapolis, MNNPI 1508851387
Payments from drug & device makers
What this record shows
The money is spread across several categories — royalties or licence payments (53.9%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. Alcon accounts for 64.1% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $37,132, 3.7 times the $10,090 reported in 2019. Among ophthalmology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 65 payments — averaging $1828.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$76K
- Dompe US, Inc.$15K
- Glaukos Corporation$12K
- Sun Pharmaceutical Industries Inc.$6K
- Avedro Inc.$3K
- Dompe Farmaceutici S.p.a.$2K
- plus $4K from 9 others
Across 17 payments — averaging $1762.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kowa Research Institute, Inc.$25K
- Samsara Vision$5K
What the payments were for
- Royalty or licence$64,00054%
- Consulting fees$18,68816%
- Speaking & faculty fees$33,08928%
- Travel & lodging$5700%
- Food & beverage$2,4792%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 7 | $76,226 |
| Dompe US, Inc. | 14 | $15,229 |
| Glaukos Corporation | 19 | $12,427 |
| Sun Pharmaceutical Industries Inc. | 6 | $5,574 |
| Avedro Inc. | 1 | $3,250 |
| Dompe Farmaceutici S.p.a. | 2 | $2,063 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $1,292 |
| Eyevance Pharmaceuticals LLC | 2 | $1,287 |
| AbbVie | 1 | $656 |
| Biotissue Holdings Inc. | 3 | $258 |
| Sight Sciences, Inc. | 2 | $252 |
| Bausch & Lomb Americas Inc. | 1 | $137 |
| Ocular Therapeutix, Inc. | 1 | $101 |
| Rxsight Inc | 1 | $39 |
| Carl Zeiss Meditec, Inc. | 1 | $36 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Oxervate$15,189
- Travoprost Intraocular Implant - iDose$7,313
- CEQUA$5,500
- CE-marked KXLA system$1,850
- KXL System$1,551
- Flarex$1,250
- ILINK$750
- Tecnis 3-piece IOL$733
- Baerveldt Glaucoma Implant (250)$536
- Tecnis IOL$536
- Compact Intuitiv$536
- Tecnis 1-piece IOL$375
- Tecnis Symphony IOL$375
- Tecnis Symphony Toric IOL$375
- Photrexa$351
- DEXTENZA$302
- TEARCARE SYSTEM$148
- MIEBO$137
- XIIDRA$137
- IC-8 Apthera IOL$137
How this compares
$118,826 in reported general payments places this provider in the 95th percentile of 330 ophthalmology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 418 | $533,514 |
| Cyclosporine | 156 | $103,919 |
| Prednisolone Acetate | 1,268 | $56,653 |
| Fluorometholone | 522 | $42,711 |
| XiidraLifitegrast | 33 | $40,163 |
| CequaCyclosporine | 36 | $28,214 |
| ValacyclovirValacyclovir Hcl | 190 | $17,632 |
| MoxifloxacinMoxifloxacin Hcl | 712 | $13,299 |
| TyrvayaVarenicline Tartrate | 12 | $11,180 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 46 | $9,503 |
| Famciclovir | 36 | $8,720 |
| Ketorolac Tromethamine | 599 | $8,549 |
| Doxycycline Hyclate | 219 | $6,898 |
| CombiganBrimonidine Tartrate/Timolol | 21 | $6,520 |
| LumiganBimatoprost | 16 | $5,859 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan, Lumigan, Alphagan P | $656 | $550,260468 claims |
| Bausch & Lomb Americas Inc.Xiidra | $137 | $40,16333 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $5,574 | $28,21436 claims |
| AlconSimbrinza | $76,226 | $5,06918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 330 ophthalmology providers in Minnesota.
Other ophthalmology in Minneapolis
- Edwin RyanMinneapolis$9.6M
- Sandra MontezumaMinneapolis$48K
- Sundeep DevMinneapolis$13K
- Silvia Orengo-NaniaMinneapolis$12K
- Robert MittraMinneapolis$6K
- David ParkeMinneapolis$6K
- Michael LeeMinneapolis$3K
- Huda SheheitliMinneapolis$3K
- Dinesh GoyalMinneapolis$3K
- Mark LobanoffSt Louis Park$6.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.